Education
About Us
Working with TipRanks
Follow Us
CureVac (CVAC)
NASDAQ:CVAC
CVAC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.37 - $5.72
Previous CloseN/A
Volume1.54M
Average Volume (3M)635.46K
Market Cap
$1.20B
Enterprise Value$306.49M
Total Cash (Recent Filing)$395.81M
Total Debt (Recent Filing)$36.03M
Price to Earnings (P/E)5.9
Beta1.29
Next Earnings
Nov 18, 2025EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding225,172,740
10 Day Avg. Volume484,814
30 Day Avg. Volume635,456
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.25
Enterprise Value/Revenue0.60
Enterprise Value/Gross Profit0.63
Enterprise Value/Ebitda1.28
Forecast
1Y Price Target
$5.25Price Target Upside-1.87% Downside
Rating ConsensusHold
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
AcquisitionBNTX announced an all-stock acquisition offer for CVAC for ~$1.25B, with CVAC shares exchanged for $5.46 in BNTX ADS – a ~55% premium to CVAC’s trailing 3-month average price.
FinancialsCVAC ended the period with €392.7mm in cash and equivalents, expected to fund operations into 2028.
Intellectual PropertyCureVac obtained a positive ruling from the European Patent Office that upheld the validity of a European patent.
Bears Say
Legal ChallengesCVAC is currently dealing with ongoing patent litigation, which adds a layer of complexity to its operations.
Operating LossOperating loss of €61.7mm was above consensus expectations.
Uncertain RevenueUncertain milestone recognition timing from partner GSK affects revenue recognition.
CureVac News
CVAC FAQ
What was CureVac’s price range in the past 12 months?
CureVac lowest stock price was $2.37 and its highest was $5.72 in the past 12 months.
What is CureVac’s market cap?
CureVac’s market cap is $1.20B.
When is CureVac’s upcoming earnings report date?
CureVac’s upcoming earnings report date is Nov 18, 2025 which is in 73 days.
How were CureVac’s earnings last quarter?
CureVac released its earnings results on Aug 15, 2025. The company reported -$0.176 earnings per share for the quarter, beating the consensus estimate of -$0.213 by $0.038.
Is CureVac overvalued?
According to Wall Street analysts CureVac’s price is currently Overvalued.
Does CureVac pay dividends?
CureVac does not currently pay dividends.
What is CureVac’s EPS estimate?
CureVac’s EPS estimate is -0.03.
How many shares outstanding does CureVac have?
CureVac has 225,172,740 shares outstanding.
What happened to CureVac’s price movement after its last earnings report?
CureVac reported an EPS of -$0.176 in its last earnings report, beating expectations of -$0.213. Following the earnings report the stock price went down -0.544%.
Which hedge fund is a major shareholder of CureVac?
Currently, no hedge funds are holding shares in CVAC
CureVac Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.25 (-1.87% Downside)
$5.25 (-1.87% Downside)
Blogger Sentiment
Bullish
CVAC Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 55.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 11.2%
Last 30 Days ▲ 11.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
90.39%
12-Months-Change
Fundamentals
Return on Equity
34.46%
Trailing 12-Months
Asset Growth
7.53%
Trailing 12-Months
Company Description
CureVac
CureVac (CVAC) is a biotechnology company focused on developing transformative medicines based on messenger RNA (mRNA) technology. The company operates primarily in the biopharmaceutical sector, leveraging its proprietary mRNA platform to develop vaccines and therapeutics for a range of diseases, including infectious diseases and cancer. CureVac's core product offerings include its mRNA-based vaccine candidates and therapeutic solutions designed to harness the body's natural mechanisms to produce proteins that can prevent or treat diseases.
CVAC Company Deck
CVAC Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
CureVac has demonstrated strong financial health with a solid cash runway and strategic partnerships, particularly with GSK. Significant progress in oncology and patent validation are positive indicators. However, operational challenges, including a major restructuring and associated costs, pose concerns.View all CVAC earnings summariesCVAC Stock 12 Month Forecast
Average Price Target
$5.25
▼(-1.87% Downside)
Technical Analysis
Xencor
―
Vir Biotechnology
―
Nurix Therapeutics
―
Praxis Precision Medicines
―
AbCellera Biologics
―
Ownership Overview
― Insiders
0.06% Mutual Funds
2.02% Other Institutional Investors
96.40% Public Companies and
Individual Investors